Hostname: page-component-5db58dd55d-m58mf Total loading time: 0 Render date: 2026-05-30T14:20:45.577Z Has data issue: false hasContentIssue false
  • English
  • Français

Recurring déjà vu associated with 5-hydroxytryptophan

Published online by Cambridge University Press:  24 June 2014

Seema Kalra ,
Andrew Chancellor  and
Adam Zeman
Seema Kalra
Affiliation:
Department of Neurology, Newcastle General Hospital, Newcastle, UK
Andrew Chancellor
Affiliation:
Department of Neurology, Bay of Plenty District Health Board, Tauranga, New Zealand
Adam Zeman*
Affiliation:
Cognitive and Behavioural Neurology Research Group, Peninsula Medical School, Mardon Centre, Exeter, UK
*
Professor Adam Zeman, Peninsula Medical School, Exeter EX2 4UD, UK. Tel: 01392-208581/208583; Fax: 01392-662929; E-mail: adam.zeman@pms.ac.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Déjà vu occurs both in normal experience and as a neuropsychiatric symptom. Its pathogenesis is partially understood. We describe an iatrogenic case with implications for the neuropharmacological basis of déjà vu.

Case presentation:

A 42-year-old woman received 5-hydroxytryptophan, in combination with carbidopa, as treatment for palatal tremor, on two occasions, separated by 1 week. On each occasion, she experienced intense, protracted déjà vu, lasting for several hours. We discuss her case in relation to the neuroanatomical and neuropharmacological basis of déjà vu.

Conclusion:

The serotonergic system is involved in the genesis of déjà vu.

Keywords

déjà vecudéjà vumemorypalatal tremorserotonin

Information

Type
Case report
Information
Acta Neuropsychiatrica , Volume 19 , Issue 5 , October 2007 , pp. 311 - 313
Copyright
Copyright © 2007 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Neppe, VM. The concept of déjà vu. Parapsychol J S Afr 1983;4:1–10. Google Scholar
Bhatt, M, Snow, B, Varelas, M, Calne, D. Palatal myoclonus: treatment with 5-hydroxytryptophan and carbidopa. Mov Disord 1990;5:339–340. CrossRefGoogle ScholarPubMed
Bancaud, J, Brunet-Bourgin, F, Chauvel, P. Anatomical origin of déjà vu and vivid ‘‘memories’’ in human temporal lobe epilepsy. Brain 1994;117:71–90. CrossRefGoogle ScholarPubMed
Bartolomei, F, Barbeau, E, Gavaret, Met al. Cortical stimulation study of the role of rhinal cortex in déjà vu and reminiscence of memories. Neurology 2004;63:858–864. CrossRefGoogle ScholarPubMed
Spatt, J. Déjà vu: possible parahippocampal mechanisms. J Neuropsychiatry Clin Neurosci 2002;14:6–10. CrossRefGoogle ScholarPubMed
Moulin, CJ, Conway, MA, Thompson, RG, James, N, Jones, RW. Disordered memory awareness: recollective confabulation in two cases of persistent déjà vecu. Neuropsychologia 2005;43:1362–1378. CrossRefGoogle ScholarPubMed
Meneses, A. Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Ther Exp 1998;9:275–289. Google ScholarPubMed
Taiminem, T, Jääskeläinen, SK. Intense and recurrent déjà vu experiences related to amantadine and phenylpropanolamine in a healthy male. J Neurosci 2001;8:460–462. Google Scholar
Arvano, VL, Liang, X, Russo, A, Wang, RY. LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex. Eur J Neurosci 1999;11:3064–3072. CrossRefGoogle Scholar
Gardiner, JM. Episodic memory and autonoetic consciousness, Philos Trans R Soc Series B 2001;1351–1361. CrossRefGoogle ScholarPubMed
Tracy, D, Shergill, SS. Imaging auditory hallucinations in schizophrenia. Acta Neuropsychiatr 2006;18:71–78. CrossRefGoogle Scholar